Introduction: Current treatment of Parkinson's disease (PD) is limited to symptomatic
dopaminergic therapy, while no interventions have been shown to slow down disease …

Thiazolidinediones (TZDs) are peroxisome proliferator‐activated receptor (PPAR)‐γ
agonists commonly used as insulin‐sensitizing drugs for the treatment of type 2 diabetes. In …

The oral antidiabetic thiazolidinediones exert protective effects in models of Parkinson's
disease and other neurological diseases. While the antidiabetic effect is due to activation of …

Parkinson's disease (PD) is amongst the most frequent neurodegenerative disorders, the
main pathologic hallmark of which is the degeneration of the substantia nigra pars …

Peroxisome proliferator-activated receptor (PPAR) γ is a potential pharmacological target for
disease-modification in Parkinson's disease (PD), mainly acting by modulating the …

Thiazolidinedione (TZD) class of peroxisome proliferator receptor gamma (PPAR-γ) agonists
display neuroprotective effects in experimental Parkinson's disease (PD) models. Neurons …

A dysregulated response of the neuroimmune system is a main contributor to the
progression of neurodegeneration in Parkinson's disease (PD). Recent findings suggest that …

Parkinson's disease (PD) is a chronic and progressive neurological disorder characterized
by the degeneration of dopaminergic neurons in the substantia nigra pars compacta (SNc) …

The results of a futility trial, which used the PPAR-γ receptor agonist pioglitazone in an
attempt to modify disease progression in Parkinson disease, do not support initiation of …

Background It has been found that thiazolidinediones (TZDs) may play a protective role in
animal models of Parkinson's disease (PD), while the results remain controversial whether …